ROS1 and non-small cell lung carcinoma: Single nucleotide mutations in the ROS1 kinase domain, such as p.D2033N, p.G2032R/K, p.L2026M, p.L2155S, and p.S1986F/Y, have been reported leading to acquired resistance to ROS1 TKIs in ROS1 fusion-positive NSCLC through preclinical and clinical studies (167–171).